News & Events
Here you can read about our latest research, awards and insights.
Meny
Here you can read about our latest research, awards and insights.
The Anders Jahre Award for Medical Research 2024 is given to Professor Lauri Aaltonen, University of Helsinki, and Professor Thomas Helleday, Karolinska Institutet. The Anders Jahre Award for Young Researchers goes to Associate Professor Nicolai Albrechtsen and Associate Professor Nicholas Taylor, both University of Copenhagen.
Thomas Helleday says: “I am deeply honoured to be recognised by the Anders Jahre Prize. The credit for the achievement goes to the entire team that dared to break new grounds and not follow well-trodden paths. Our new research directions have been met by scepticism from researchers that felt challenged or did not look deeply into the scientific details. Now, many of these early ideas have developed into well-established treatments or research areas. My hope is that the prize may serve as an inspiration for young researchers to try unconventional approaches to challenge the big questions”.
Read more here
The Wallenberg Scholars program aims to provide leading researchers in Sweden with grants for free research. Following a comprehensive international peer review, the Foundation has chosen to fund 118 researchers for five years, providing up to SEK 18 million each for researchers in theoretical subjects and up to SEK 20 million each for researchers in experimental subjects. Of the 29 medical researchers awarded this year’s Scholar grants, 19 are active at Karolinska Institutet. Thomas Helleday is one of the awardees, receiving SEK 20 million during 5 years.
As a Wallenberg Scholar, Professor Helleday hopes to develop a new type of therapeutic method for treating diseases and ageing. His aim is to produce more efficacious drugs through the development of new, biochemical treatment methods.
Read more here
We are extremely proud to publish in Nature Metabolism the detailed mechanism on how our MTHFD1/2 inhibitors work and why they specifically kill cancer cells. This constitutes a new major attack on cancer and we are excited to see how it works in the clinic.
Read the full article here